U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    48,732.23
    -6,199.68 (-11.29%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021.

Details for all three investor conferences are as follows:

39th Annual J.P. Morgan Healthcare Conference - Corporate Presentation

Date:

January 14, 2021

Time:

2:00 p.m. ET

Webcast:

Audio-only Link to Webcast Here

2021 LifeSci Advisors - Corporate Access Event

Date:

January 7-13, 2021

Time:

Management available for 1x1 meetings

H.C. Wainwright BioConnect 2021 Conference - Corporate Presentation

Date:

January 11-14, 2021

The session time is on-demand, beginning Monday January 11 starting 6:00 a.m. ET.

To register and view the presentation, please click here.

A replay for all conferences will be available on the Events and Presentations section investor section of the Infinity Pharmaceuticals website https://investors.infi.com/events-and-presentations/upcoming-events following the conference.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.

Tecentriq® is a registered trademark of Genentech, Inc.

Abraxane® is a registered trademark of Abraxis BioScience, LLC.

Avastin® is a registered trademark of Genentech, Inc.

Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005217/en/

Contacts

Ashley Robinson
LifeSci Advisors, LLC
617-775-5956